The experience of physicians in pharmacogenomic clinical decision support within eight German university hospitals [0.03%]
八所德国大学附属医院医师关于药物基因组学临床决策支持的应用体验
Marc Hinderer,Martin Boeker,Sebastian A Wagner et al.
Marc Hinderer et al.
Aim: The aim of this study was to assess the physicians' attitude, their knowledge and their experience in pharmacogenomic clinical decision support in German hospitals. ...
Observational Study
Pharmacogenomics. 2017 Jun;18(8):773-785. DOI:10.2217/pgs-2017-0027 2017
Chiara Fabbri
Chiara Fabbri
Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients [0.03%]
药物基因学和乳腺癌患者的芳香化酶抑制剂引起的副作用
Valentina Sini,Andrea Botticelli,Gianluigi Lunardi et al.
Valentina Sini et al.
This paper reviews genetic variations mainly related to the onset of adverse events during aromatase inhibitors in early breast cancer. Genetic variability could occur at different steps. The analysis included studies that involved breast c...
Influence of two variants of CYP450 oxidoreductase on the stable dose of acenocoumarol in a Spanish population [0.03%]
两种CYP450氧化还原酶变异体对西班牙人群乙腈香豆素稳定剂量的影响
Hoi Y Tong,Alberto M Borobia,José Carlos Martínez Ávila et al.
Hoi Y Tong et al.
Aim: To evaluate the influence of two variants of P450 oxidoreductase (POR), rs2868177 and POR*28, on the stable dosage of acenocoumarol. Patients & metho...
Observational Study
Pharmacogenomics. 2017 Jun;18(8):797-805. DOI:10.2217/pgs-2017-0021 2017
Sumi Elsa John,Dinu Antony,Muthukrishnan Eaaswarkhanth et al.
Sumi Elsa John et al.
Assessing the distinct prevalence or absence of genetic variants associated with differential response to the anticoagulant medication of warfarin in different population groups is actively pursued by pharmacogenomics community. Populations...
The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients [0.03%]
MTHFR基因C677T多态性对儿童骨肉瘤甲氨蝶呤致毒性的作用研究
Loes Lambrecht,Charlotte Sleurs,Veerle Labarque et al.
Loes Lambrecht et al.
Aim: Osteosarcoma patients receive high doses of methotrexate (MTX). However, pharmacogenetic information remains limited and has mainly been investigated in leukemia so far. ...
Don't think twice it's all right: tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients [0.03%]
不必迟疑一切安好：乳腺癌患者治疗中三苯氧胺与CYP2D6基因型测定的关系研究
Per Damkier
Per Damkier
Letter in resonse to: Del Re M, Rofi E, Citi V, Fidilio L, Danesi R. Should CYP2D6 be genotyped when treating with tamoxifen? Pharmacogenomics 17(18), 1967-1969 (2016).
Corrigendum [0.03%]
勘误表
Published Erratum
Pharmacogenomics. 2017 May;18(7):743-748. DOI:10.2217/pgs-2017-0025 2017
Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings? [0.03%]
是否应推荐常规检测CYP2D6和CYP2C19基因多态性以预测抗抑郁药文拉法辛在精神科患者中的疗效？
Adela Taranu,Romain Colle,Florence Gressier et al.
Adela Taranu et al.
Aim: The antidepressant venlafaxine (VEN) is metabolized by CYP2D6 and CYP2C19. The aim of this study was to assess the relevance of generalizing to daily practice the genotyping of CYP2D6 and CYP2C19 to predict VEN effic...
Multicenter Study
Pharmacogenomics. 2017 May;18(7):639-650. DOI:10.2217/pgs-2017-0003 2017
Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6 [0.03%]
药物与药物相互作用以及药物与基因互作的药剂遗传学：CYP2C9、CYP2C19和CYP2D6系统的回顾性研究
Muh Akbar Bahar,Didik Setiawan,Eelko Hak et al.
Muh Akbar Bahar et al.
Currently, most guidelines on drug-drug interaction (DDI) neither consider the potential effect of genetic polymorphism in the strength of the interaction nor do they account for the complex interaction caused by the combination of DDI and ...